NASDAQ:IONS Ionis Pharmaceuticals - IONS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $35.74 +0.85 (+2.44%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$35.08▼$35.7850-Day Range$33.58▼$41.2052-Week Range$31.46▼$48.82Volume1.09 million shsAverage Volume944,635 shsMarket Capitalization$5.11 billionP/E RatioN/ADividend YieldN/APrice Target$45.17 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ionis Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.30 Rating ScoreUpside/Downside26.4% Upside$45.17 Price TargetShort InterestN/ADividend StrengthN/ASustainability-3.58Upright™ Environmental ScoreNews Sentiment0.45Based on 5 Articles This WeekInsider TradingSelling Shares$2.96 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.97) to ($3.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector314th out of 1,004 stocksPharmaceutical Preparations Industry136th out of 489 stocks 4.2 Analyst's Opinion Consensus RatingIonis Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 5 buy ratings, 3 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $45.17, Ionis Pharmaceuticals has a forecasted upside of 26.4% from its current price of $35.74.Amount of Analyst CoverageIonis Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IONS. Previous Next 0.0 Dividend Strength Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIonis Pharmaceuticals has received a 27.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication" product. See details.Environmental SustainabilityThe Environmental Impact score for Ionis Pharmaceuticals is -3.58. Previous Next 2.5 News and Social Media Coverage News SentimentIonis Pharmaceuticals has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Ionis Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest19 people have searched for IONS on MarketBeat in the last 30 days. This is an increase of 58% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,961,208.00 in company stock.Percentage Held by InsidersOnly 2.36% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions87.32% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to decrease in the coming year, from ($2.97) to ($3.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is -18.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is -18.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 8.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ionis Pharmaceuticals (NASDAQ:IONS) StockIonis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.Read More Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IONS Stock News HeadlinesMarch 29, 2023 | finance.yahoo.comNew data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's diseaseMarch 27, 2023 | finance.yahoo.comIonis (IONS) Posts New Upbeat Data From Amyloidosis Drug StudyApril 1, 2023 | The Oxford Club (Ad)Unusual Passive Income Investment (Found on a Golf Course)Marc reveals how anyone can get into a similar opportunity for just $5.March 27, 2023 | seekingalpha.comIonis, AstraZeneca report positive outcomes from eplontersen trialMarch 27, 2023 | markets.businessinsider.comIonis Pharma Reports Positive 66-week Results Of Eplontersen Phase 3 Study In ATTRv-PNMarch 24, 2023 | msn.comWhy Is Ionis Pharmaceuticals (IONS) Down 8.4% Since Last Earnings Report?March 23, 2023 | markets.businessinsider.comCitigroup Sticks to Their Sell Rating for Ionis Pharmaceuticals (IONS)March 23, 2023 | finance.yahoo.comBiogen Pops — But Ionis Hands Back Gains — After ALS Drug Wins A Key EndorsementApril 1, 2023 | The Oxford Club (Ad)Unusual Passive Income Investment (Found on a Golf Course)Marc reveals how anyone can get into a similar opportunity for just $5.March 23, 2023 | americanbankingnews.comSanford C. Bernstein Initiates Coverage on Ionis Pharmaceuticals (NASDAQ:IONS)March 22, 2023 | finance.yahoo.comIonis Pharmaceuticals, Inc. (IONS)March 15, 2023 | finance.yahoo.comIonis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)March 7, 2023 | marketwatch.comIonis: FDA to Review Eplontersen in ATTRv-PN >IONSFebruary 23, 2023 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)February 23, 2023 | finance.yahoo.comIonis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock DownFebruary 23, 2023 | finance.yahoo.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2022 Earnings Call TranscriptFebruary 22, 2023 | finanznachrichten.deIonis Pharmaceuticals, Inc.: Ionis reports fourth quarter and full year 2022 financial resultsFebruary 22, 2023 | finance.yahoo.comIonis Pharmaceuticals (IONS) Reports Q4 Loss, Misses Revenue EstimatesFebruary 22, 2023 | finance.yahoo.comIonis reports fourth quarter and full year 2022 financial resultsFebruary 21, 2023 | finance.yahoo.comAnalyst Says Ionis' Additional Hereditary Angioedema Study Data Supports 'Highly Competitive Profile'February 21, 2023 | benzinga.comIonis Pharmaceuticals's Earnings OutlookFebruary 21, 2023 | finance.yahoo.comIonis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual MeetingFebruary 16, 2023 | finance.yahoo.comEarnings Preview: Relay Therapeutics, Inc. (RLAY) Q4 Earnings Expected to DeclineFebruary 15, 2023 | finance.yahoo.comEarnings Preview: Ionis Pharmaceuticals (IONS) Q4 Earnings Expected to DeclineFebruary 9, 2023 | finance.yahoo.comInstitutional investors in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) lost 4.6% last week but have reaped the benefits of longer-term growthFebruary 8, 2023 | finance.yahoo.comIonis to hold fourth quarter and full year 2022 financial results webcastJanuary 31, 2023 | finance.yahoo.comIonis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndromeSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IONS Company Calendar Last Earnings2/22/2023Today4/01/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IONS CUSIP46433010 CIK874015 Webwww.ionispharma.com Phone(760) 931-9200Fax760-603-2700Employees660Year FoundedN/APrice Target and Rating Average Stock Price Forecast$45.17 High Stock Price Forecast$67.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+26.4%Consensus RatingHold Rating Score (0-4)2.30 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-269,720,000.00 Net Margins-45.75% Pretax Margin-43.92% Return on Equity-43.01% Return on Assets-10.84% Debt Debt-to-Equity Ratio2.06 Current Ratio7.07 Quick Ratio7.00 Sales & Book Value Annual Sales$587 million Price / Sales8.70 Cash FlowN/A Price / Cash FlowN/A Book Value$4.03 per share Price / Book8.87Miscellaneous Outstanding Shares142,950,000Free Float139,580,000Market Cap$5.11 billion OptionableOptionable Beta0.57 Key ExecutivesBrett P. MoniaChief Executive Officer & DirectorOnaiza Cadoret-ManierEVP, Chief Product Strategy & Operations OfficerElizabeth L. HougenChief Financial Officer & Executive VP-FinanceC. Frank BennettChief Scientific Officer & Executive VPSanjay BhanotChief Medical Officer & SVPKey CompetitorsAlkermesNASDAQ:ALKSMadrigal PharmaceuticalsNASDAQ:MDGLAmicus TherapeuticsNASDAQ:FOLDIronwood PharmaceuticalsNASDAQ:IRWDUnited TherapeuticsNASDAQ:UTHRView All CompetitorsInsiders & InstitutionsETF Managers Group LLCBought 7,649 shares on 3/23/2023Ownership: 0.005%B. Riley Wealth Advisors Inc.Bought 1,404 shares on 3/15/2023Ownership: 0.006%NatixisBought 25,597 shares on 2/24/2023Ownership: 0.112%B. Riley Wealth Advisors Inc.Bought 1,404 shares on 2/21/2023Ownership: 0.006%Northwestern Mutual Wealth Management Co.Sold 330 shares on 2/21/2023Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions IONS Stock - Frequently Asked Questions Should I buy or sell Ionis Pharmaceuticals stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 2 sell ratings, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" IONS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares. View IONS analyst ratings or view top-rated stocks. What is Ionis Pharmaceuticals' stock price forecast for 2023? 10 Wall Street research analysts have issued 1-year target prices for Ionis Pharmaceuticals' stock. Their IONS share price forecasts range from $27.00 to $67.00. On average, they anticipate the company's share price to reach $45.17 in the next twelve months. This suggests a possible upside of 26.4% from the stock's current price. View analysts price targets for IONS or view top-rated stocks among Wall Street analysts. How have IONS shares performed in 2023? Ionis Pharmaceuticals' stock was trading at $37.77 at the beginning of the year. Since then, IONS stock has decreased by 5.4% and is now trading at $35.74. View the best growth stocks for 2023 here. When is Ionis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our IONS earnings forecast. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced its earnings results on Wednesday, February, 22nd. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.69. The business earned $152 million during the quarter, compared to analyst estimates of $160.21 million. Ionis Pharmaceuticals had a negative net margin of 45.75% and a negative trailing twelve-month return on equity of 43.01%. Ionis Pharmaceuticals's revenue was down 65.5% on a year-over-year basis. During the same period last year, the firm earned $1.41 earnings per share. What ETFs hold Ionis Pharmaceuticals' stock? ETFs with the largest weight of Ionis Pharmaceuticals (NASDAQ:IONS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Direxion mRNA ETF (MSGR), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Biotechnology & Genome ETF (PBE), Franklin Genomic Advancements ETF (HELX), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Virtus LifeSci Biotech Products ETF (BBP) and Principal Healthcare Innovators ETF (BTEC). What guidance has Ionis Pharmaceuticals issued on next quarter's earnings? Ionis Pharmaceuticals updated its FY 2023 earnings guidance on Wednesday, February, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $672.18 million. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD). What is Ionis Pharmaceuticals' stock symbol? Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS." How do I buy shares of Ionis Pharmaceuticals? Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ionis Pharmaceuticals' stock price today? One share of IONS stock can currently be purchased for approximately $35.74. How much money does Ionis Pharmaceuticals make? Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $5.11 billion and generates $587 million in revenue each year. The company earns $-269,720,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. How many employees does Ionis Pharmaceuticals have? The company employs 660 workers across the globe. How can I contact Ionis Pharmaceuticals? Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The official website for the company is www.ionispharma.com. The company can be reached via phone at (760) 931-9200, via email at wwalke@ionisph.com, or via fax at 760-603-2700. This page (NASDAQ:IONS) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.